Vaccitech has appointed a new chief medical officer, Mariem Charafeddine, to oversee the development of its growing clinical pipeline of T Cell-inducing viral vector vaccines.
Mariem brings over 15 years’ experience in the biopharmaceutical industry, spent both advancing the clinical development and commercialisation of infectious disease products, and in delivering post-marketing monitoring of licensed medical products.
She has previously worked in international medical leadership roles and drug development in infectious diseases, and joins Vaccitech after six years at Abbvie, where she most recently served as medical director for pharmacovigilance and patient safety sciences, infectious diseases and neurosciences.
"We are delighted to have Mariem join our team as we advance towards the Phase 2b read-outs of our lead clinical program in influenza,” said Tom Evans, Vaccitech CEO. “Her wide-ranging clinical development and post-marketing expertise in infectious diseases also puts us in great stead ahead of first in human studies for our HPV and HBV therapeutics. We look forward to her input on how best to develop our vaccines for the patients that need them.”
Mariem will oversee the development of Vaccitech’s growing clinical-stage pipeline and will help implement the global clinical development strategy and medical plans across Vaccitech's therapeutic and prophylactic vaccine products.
